# Viridian Therapeutics, Inc.\\DE: overview

VRDN · Nasdaq · CIK 1590750 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vrdn.md) · [Financials](/companies/vrdn/financials.md) · [Filings](/companies/vrdn/filings.md) · [Insiders](/companies/vrdn/insiders.md)

Latest reported revenue: [$284.0k](/filings/0001590750-26-000018.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001590750-26-000018).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.1](/filings/0001590750-25-000020.md) | [0.1 d](/filings/0001590750-26-000007.md) | [0.1](/filings/0001590750-26-000012.md) | [0.1](/filings/0001590750-26-000018.md) | [70.6](/filings/0001590750-25-000020.md) | [0.1 d](/filings/0001590750-26-000007.md) | [0.1](/filings/0001590750-26-000012.md) | [0.3](/filings/0001590750-26-000018.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(97069.8%)](/filings/0001590750-25-000020.md) | [(121488.9%) d](/filings/0001590750-26-000007.md) | [(130369.4%)](/filings/0001590750-26-000012.md) | [(142356.0%)](/filings/0001590750-26-000018.md) | [(56.7%)](/filings/0001590750-25-000020.md) | [(92991.7%) d](/filings/0001590750-26-000007.md) | [(82389.4%)](/filings/0001590750-26-000012.md) | [(44460.6%)](/filings/0001590750-26-000018.md) |
| Net margin | % | [(89173.3%)](/filings/0001590750-25-000020.md) | [(110729.2%) d](/filings/0001590750-26-000007.md) | [(120711.1%)](/filings/0001590750-26-000018.md) | [(134313.3%)](/filings/0001590750-26-000018.md) | [(49.0%)](/filings/0001590750-25-000020.md) | [(91178.0%) d](/filings/0001590750-26-000007.md) | [(74397.9%)](/filings/0001590750-26-000018.md) | [(44760.2%)](/filings/0001590750-26-000018.md) |
| Diluted EPS | $ per share | [(1.15)](/filings/0001590750-24-000023.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Free cash flow | $m | [(68.0) d](/filings/0001590750-25-000020.md) | [(73.4) d](/filings/0001590750-26-000007.md) | [(92.7)](/filings/0001590750-26-000012.md) | [(75.4) d](/filings/0001590750-26-000018.md) | [(84.7) d](/filings/0001590750-25-000020.md) | [(24.0) d](/filings/0001590750-26-000007.md) | [(120)](/filings/0001590750-26-000012.md) | [(107) d](/filings/0001590750-26-000018.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.0](/filings/0001590750-24-000007.md) | [1.8](/filings/0001590750-25-000004.md) | [0.3](/filings/0001590750-26-000007.md) | [0.3](/filings/0001590750-26-000007.md) | [70.8](/filings/0001590750-26-000007.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(2690.8%)](/filings/0001590750-24-000007.md) | [(7579.2%)](/filings/0001590750-25-000004.md) | [(81035.0%)](/filings/0001590750-26-000007.md) | [(99018.2%)](/filings/0001590750-26-000007.md) | [(512.9%)](/filings/0001590750-26-000007.md) |
| Net margin | % | [(2680.2%)](/filings/0001590750-24-000007.md) | [(7329.2%)](/filings/0001590750-25-000004.md) | [(75711.5%)](/filings/0001590750-26-000007.md) | [(89387.1%)](/filings/0001590750-26-000007.md) | [(483.6%)](/filings/0001590750-26-000007.md) |
| Diluted EPS | $ per share | [(6.66)](/filings/0001590750-24-000007.md) | [(4.05)](/filings/0001590750-24-000007.md) | [(5.31)](/filings/0001590750-24-000007.md) | not reported | not reported |
| Free cash flow | $m | [(54.9)](/filings/0001590750-24-000007.md) | [(94.6)](/filings/0001590750-25-000004.md) | [(185)](/filings/0001590750-26-000007.md) | [(233)](/filings/0001590750-26-000007.md) | [(277)](/filings/0001590750-26-000007.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vrdn/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $305.0m | 16,604,740 |  | Added +1,225,363 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $157.1m | 8,551,488 |  | Added +720,013 |
| [Bellevue Group AG](/funds/1674546.md) | 2026-06-30 | $123.7m | 6,731,909 |  | Added +5,765 |
| [Paradigm Biocapital Advisors LP](/funds/1855655.md) | 2026-06-30 | $123.5m | 6,723,788 |  | Added +3,574,895 |
| [Kynam Capital Management, LP](/funds/1907884.md) | 2026-06-30 | $118.6m | 6,453,877 |  | Added +4,112,225 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $112.5m | 6,124,976 |  | Added +1,452,091 |
| [Fairmount Funds Management LLC](/funds/1802528.md) | 2026-06-30 | $93.5m | 5,090,928 |  | Added +1,176,470 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $84.1m | 4,576,860 |  | Added +409,659 |
| [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $66.0m | 3,592,740 |  | Added +2,198,796 |
| [Venrock Adviser, LLC](/funds/1615982.md) | 2026-06-30 | $59.8m | 3,257,917 |  | Reduced −624,792 |

## Recent filings

[All 811 filings](/companies/vrdn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 07:31 ET | [10-Q](/filings/0001590750-26-000018.md) | Quarterly report, period 2026-06-30 | 0001590750-26-000018 |
| 2026-08-06 | 07:05 ET | [8-K](/filings/0001193125-26-336691.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-336691 |
| 2026-06-29 | 18:18 ET | [8-K](/filings/0001193125-26-286273.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-286273 |
| 2026-06-03 | 07:00 ET | [8-K](/filings/0001193125-26-254560.md) | 5.07 Shareholder vote results | 0001193125-26-254560 |
| 2026-05-28 | 16:05 ET | [8-K](/filings/0001193125-26-245186.md) | 1.02 Termination of a material agreement | 0001193125-26-245186 |
| 2026-05-26 | 16:05 ET | [8-K](/filings/0001193125-26-239246.md) | 1.01 Entry into a material agreement | 0001193125-26-239246 |
| 2026-05-13 | 16:30 ET | [SCHEDULE 13D/A](/filings/0001104659-26-060292.md) | Ownership report, active investor, amended | 0001104659-26-060292 |
| 2026-05-11 | 16:02 ET | [8-K](/filings/0001193125-26-216709.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-216709 |
| 2026-05-05 | 07:56 ET | [8-K](/filings/0001193125-26-205099.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-205099 |
| 2026-05-05 | 07:05 ET | [10-Q](/filings/0001590750-26-000012.md) | Quarterly report, period 2026-03-31 | 0001590750-26-000012 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001590750-26-000007.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/4f6ac60c-7448-49fe-98fe-65aeed942b09)

## About the filer

- CIK: 1590750
- Tickers: VRDN
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.